Camizestrant vs Fulvestrant

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Camizestrant · Etcamah

Marketed by AstraZeneca

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Reliable signal

NCT04964934 · Phase 3 · active, not recruiting

This was a randomized, triple-blinded, placebo-controlled Phase III trial with an active comparator (continued aromatase inhibitor) in 315 patients, using progression-free survival (a hard clinical endpoint) as the primary measure. The result, reported via an external source since CT.gov has not yet posted results, showed a clear and highly statistically significant benefit for camizestrant (median PFS 16.0 vs 9.2 months, HR 0.44, p<0.00001), meeting the primary endpoint in the favorable direction.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2027 · NCT04644068 (registry estimate)

Reported efficacy

Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) (From randomization until the earlier of the progression event or death (approximately 2 years)): SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 (met)

Result source: NCT04964934

Fulvestrant · Faslodex

Marketed by AstraZeneca

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT00635713 · Phase 3 · completed

The trial randomized an estimated 588 participants and used double blinding to compare two active treatment groups: fulvestrant 125 mg plus anastrozole versus fulvestrant 250 mg plus anastrozole. Its primary endpoint was time to tumor progression, a clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

ClinicalTrials.gov records both arms as fulvestrant plus anastrozole. The published North American Trial 0021 (Osborne 2002) randomized fulvestrant 250 mg monthly against anastrozole 1 mg daily, double-blind and double-dummy.

Next expected readout: December 2026 · NCT07163481 (registry estimate)

Reported efficacy

Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59) (met)

Result source: NCT01602380

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCamizestrantFulvestrant
PFS, median—Trial running · NCT077174504.7 vs 3.8+0.9 vs placebon 146NCT00390455
17 other results
OS, median—Trial running · NCT0771745029.9 vs 26.4+3.5 vs placebon 146NCT00390455
10 other results
ORR—Trial running · NCT0771745020% vs 9%+11 vs placebon 101NCT00390455
9 other results
  • 13% vs 23% n 32 · Phase 3 · secondary NCT00390455
  • 38% vs 17% n 8 · Phase 3 · secondary NCT00390455
  • 46.1% vs 44.9% 500 mg · n 193 · Phase 3 · secondary NCT01602380
  • 29.9% n 45 · Phase 2 · primary NCT02860000
  • 32.9% vs 13.9% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 13.9% vs 13.9% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
  • 19.3% n 119 · Phase 2 · secondary NCT03056755
  • 17.5% n 114 · Phase 2 · secondary NCT03056755
  • 25.2% n 115 · Phase 2 · secondary NCT03056755
Clinical benefit rate—Trial running · NCT0771745078.3% vs 74.1%vs Anastrozole500 mg · n 230NCT01602380
9 other results
  • 55% vs 55.1% n 258 · Phase 3 · secondary NCT00256698
  • 70% n 345 · Phase 3 · secondary NCT00075764
  • 73% n 349 · Phase 3 · secondary NCT00075764
  • 58.2% vs 38% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 45.6% vs 38% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
  • 28.9% wk 24 · n 45 · Phase 2 · secondary NCT02860000
  • 46.2% n 119 · Phase 2 · secondary NCT03056755
  • 35.1% n 114 · Phase 2 · secondary NCT03056755
  • 38.3% n 115 · Phase 2 · secondary NCT03056755

PFS, median

Camizestrant
—Trial running · NCT07717450
Fulvestrant
4.7 vs 3.8+0.9 vs placebon 146NCT00390455
17 other results

OS, median

Camizestrant
—Trial running · NCT07717450
Fulvestrant
29.9 vs 26.4+3.5 vs placebon 146NCT00390455
10 other results

ORR

Camizestrant
—Trial running · NCT07717450
Fulvestrant
20% vs 9%+11 vs placebon 101NCT00390455
9 other results
  • 13% vs 23% n 32 · Phase 3 · secondary NCT00390455
  • 38% vs 17% n 8 · Phase 3 · secondary NCT00390455
  • 46.1% vs 44.9% 500 mg · n 193 · Phase 3 · secondary NCT01602380
  • 29.9% n 45 · Phase 2 · primary NCT02860000
  • 32.9% vs 13.9% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 13.9% vs 13.9% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
  • 19.3% n 119 · Phase 2 · secondary NCT03056755
  • 17.5% n 114 · Phase 2 · secondary NCT03056755
  • 25.2% n 115 · Phase 2 · secondary NCT03056755

Clinical benefit rate

Camizestrant
—Trial running · NCT07717450
Fulvestrant
78.3% vs 74.1%vs Anastrozole500 mg · n 230NCT01602380
9 other results
  • 55% vs 55.1% n 258 · Phase 3 · secondary NCT00256698
  • 70% n 345 · Phase 3 · secondary NCT00075764
  • 73% n 349 · Phase 3 · secondary NCT00075764
  • 58.2% vs 38% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 45.6% vs 38% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
  • 28.9% wk 24 · n 45 · Phase 2 · secondary NCT02860000
  • 46.2% n 119 · Phase 2 · secondary NCT03056755
  • 35.1% n 114 · Phase 2 · secondary NCT03056755
  • 38.3% n 115 · Phase 2 · secondary NCT03056755
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Camizestrant
SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 NCT04964934 · Phase 3 · design grade: strong · publication or press release
Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81) NCT04588298 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Camizestrant: 4 of 4 rows · Fulvestrant: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCamizestrantFulvestrant
Dropout rate
3.3%75 mga
NCT04588298 · Phase 2
show 4 more results
3.3%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
89.1%500 mga
NCT01602380 · Phase 3 · combination
show 40 more results
47.5%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
31.7%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
21.2%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
1.2%
NCT02447328 · Phase 4 · registry result, not featured evidence
0%Faslodex + Arimidex
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
0%Faslodex + Placebo
NCT00253422 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
—Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
—Anastrozole & Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneArm I Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
n/a: no completion milestoneArm II Anastrozole and Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
21.6%
NCT00390455 · Phase 3 · registry result, not featured evidence
32.4%500 mg
NCT01300351 · Phase 3 · registry result, not featured evidence
64.7%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
1.1%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
87.5%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
8.2%
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
99.2%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
100%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
92.1%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
10.1%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
6.3%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
1.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
1.6%
NCT02536742 · Phase 2 · registry result, not featured evidence
—Crossover: Neratinib + Fulvestrant
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
9.1%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
12.5%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
3.4%Arm B: Fulvestrant + Bortezomib
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
—Arm C: Crossover From Arm A at Pro
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
0%
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
69.6%500 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
76.6%250 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
66.7%250 mg + loading dose
NCT00313170 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
—500 mga
NCT01602380 · Phase 3 · combination
show 40 more results
10%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
3.2%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
1.5%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
—
NCT02447328 · Phase 4 · registry result, not featured evidence
—Faslodex + Arimidex
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
—Faslodex + Placebo
NCT00253422 · Phase 3 · registry result, not featured evidence
2%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
—Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
—Anastrozole & Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
1.4%Arm I Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
3.4%Arm II Anastrozole and Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
11.5%
NCT00390455 · Phase 3 · registry result, not featured evidence
0%500 mg
NCT01300351 · Phase 3 · registry result, not featured evidence
5%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
—
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
—
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
—
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
15.7%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
11.1%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
10.3%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
—
NCT02536742 · Phase 2 · registry result, not featured evidence
—Crossover: Neratinib + Fulvestrant
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
—Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
—Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
—Arm B: Fulvestrant + Bortezomib
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
—Arm C: Crossover From Arm A at Pro
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
—
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
—
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
0%500 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
2.1%250 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
3.9%250 mg + loading dose
NCT00313170 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
0%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
17.1%500 mga
NCT01602380 · Phase 3 · combination
show 40 more results
25%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
7.9%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
6.6%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
11.1%
NCT02447328 · Phase 4 · registry result, not featured evidence
16.9%Faslodex + Arimidex
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
13.8%Faslodex + Placebo
NCT00253422 · Phase 3 · registry result, not featured evidence
14.1%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
6.2%Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
13.8%Anastrozole & Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
—Arm I Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
—Arm II Anastrozole and Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
8.5%
NCT00390455 · Phase 3 · registry result, not featured evidence
3.7%500 mg
NCT01300351 · Phase 3 · registry result, not featured evidence
15.6%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
38%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
15.7%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
25%
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
29.1%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
0%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
38.1%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30.2%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
19.5%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
30.8%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
27.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
73%
NCT02536742 · Phase 2 · registry result, not featured evidence
0%Crossover: Neratinib + Fulvestrant
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
18.2%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
37.5%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
10.5%Arm B: Fulvestrant + Bortezomib
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
18.5%Arm C: Crossover From Arm A at Pro
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
6.3%
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
23.1%
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
8.7%500 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
8.5%250 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
18%250 mg + loading dose
NCT00313170 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
75 mga
nausea 13.3%
fatigue 6.7%
headache 6.7%
NCT04588298 · Phase 2
show 4 more results
75 mg
visual impairment 20%
headache 10%
photopsia 10%
NCT04588298 · Phase 2
300 mg
hypertension 23.1%
visual impairment 23.1%
photopsia 15.4%
NCT04588298 · Phase 2
150 mg
visual impairment 15.2%
diplopia 12.1%
photopsia 12.1%
NCT04588298 · Phase 2
150 mg
visual impairment 24.1%
diplopia 17.2%
hypertension 13.8%
NCT04588298 · Phase 2
500 mga
arthralgia 18.4%
fatigue 12.7%
hot flush 11.4%
NCT01602380 · Phase 3 · combination
show 33 more results
hyperglycaemia 90%
stomatitis 37.5%
diarrhoea 35%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 28.6%
anaemia 22.2%
fatigue 20.6%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 29.9%
neutropenia 24.8%
anaemia 23.4%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
myalgia 12.3%
nausea 12.3%
back pain 11.1%
NCT02447328 · Phase 4 · registry result, not featured evidence
lethargy 64.5%
arthralgia 42%
hot flush 37.2%
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
lethargy 64.4%
vomiting 44.9%
arthralgia 43.6%
NCT00253422 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 63.1%
fatigue 51%
hypertension 36.9%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
fatigue (asthenia, lethargy, malaise) 60.2%
hot flashes/flushes 45.7%
pain - joint 45.1%
NCT00075764 · Phase 3 · registry result, not featured evidence
fatigue (asthenia, lethargy, malaise) 63.2%
hot flashes/flushes 54.3%
pain - joint 44%
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
diarrhea 62.4% (placebo 21.9%)
fatigue 55.3% (placebo 53.3%)
rash acneiform 41.1% (placebo 4.4%)
NCT00390455 · Phase 3 · registry result, not featured evidence
500 mg
injection site reaction 11%
pyrexia 10.1%
fatigue 8.3%
NCT01300351 · Phase 3 · registry result, not featured evidence
arthralgia 11.7%
fatigue 10.5%
nausea 9%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 92.4%
white blood cell decreased 87%
fatigue 84.8%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 92.2%
nausea 52.9%
stomatitis 41.2%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
fatigue 83.3%
anemia 62.5%
neutrophil count decreased 60.4%
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 64.6%
hyperglycaemia 59.8%
nausea 46.5%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
asthenia 100%
blood creatinine increased 100%
diarrhoea 100%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 68.3%
hyperglycaemia 64.3%
nausea 54%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
hyperglycaemia 67.5%
diarrhoea 54%
nausea 40.5%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 70%
hyperglycaemia 60%
fatigue 50%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
150 mg + 8 mg/kg
diarrhoea 77.9%
fatigue 53.2%
nausea 41.6%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
150 mg + 8 mg/kg + 500 mg
diarrhoea 79.5%
fatigue 57.7%
nausea 48.7%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
white blood cell count decreased 96.3%
neutrophil count decreased 87%
anemia 79.6%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
vomiting 60%
anorexia 40%
constipation 40%
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
diarrhea 81.8%
anorexia 63.6%
aspartate aminotransferase increased 45.5%
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
diarrhea 91.7%
fatigue 50%
nausea 50%
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
hemoglobin - low 61.4%
thrombocytopenia 61.4%
nausea 59.6%
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
hemoglobin - low 55.6%
thrombocytopenia 55.6%
diarrhea 51.9%
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
fatigue 53.1%
nausea 50%
achiness 43.8%
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
fatigue 76.9%
anorexia 61.5%
pain 53.8%
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
500 mg
back pain 15.2%
fatigue 15.2%
nausea 15.2%
NCT00313170 · Phase 2 · registry result, not featured evidence
250 mg
nausea 25.5%
hot flush 19.1%
cough 12.8%
NCT00313170 · Phase 2 · registry result, not featured evidence
250 mg + loading dose
fatigue 22%
nausea 18%
back pain 16%
NCT00313170 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Fulvestrant

PFS 16.6 vs 13.8 Anastrozole months500 mg
time to event · months
NCT01602380 · Phase 3 · combination
show 9 more results
8.3 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
5.7 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
4.8 vs 3.5 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence
4.1 vs 3.5 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
7.5 vs 9.4 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
8 vs 10.6 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
4.7 vs 3.8 placebo months
NCT00390455 · Phase 3 · registry result, not featured evidence
4.1 vs 3.8 placebo months
NCT00390455 · Phase 3 · registry result, not featured evidence
5.9 vs 3.3 placebo months
NCT00390455 · Phase 3 · registry result, not featured evidence
All-cause Mortality 68.3% (n=230) vs 67.7% (n=232) Anastrozole500 mg
absolute value · percentage points
NCT01602380 · Phase 3 · combination
ORR 46.1% (n=193) vs 44.9% (n=196) Anastrozole500 mg
responder rate · % of participants
NCT01602380 · Phase 3 · combination
show 5 more results
32.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
13.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
20% (n=101) vs 9% (n=103) placebo
NCT00390455 · Phase 3 · registry result, not featured evidence
13% (n=32) vs 23% (n=32) placebo
NCT00390455 · Phase 3 · registry result, not featured evidence
38% (n=8) vs 17% (n=13) placebo
NCT00390455 · Phase 3 · registry result, not featured evidence
Duration of Response 20 vs 13.2 Anastrozole months500 mg
time to event · months
NCT01602380 · Phase 3 · combination
show 6 more results
12.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
9.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
10.2 vs 12.8 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence
8.7 vs 12.8 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
9.7 vs 11.2 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
22.3 vs 18.2 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
Clinical Benefit 78.3% (n=230) vs 74.1% (n=232) Anastrozole500 mg
responder rate · % of participants
NCT01602380 · Phase 3 · combination
show 3 more results
58.2% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
45.6% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
55% (n=258) vs 55.1% (n=256) Anastrozole
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
ORR 7.1% (n=226) vs 4.2% (n=239) Exemestane
event count · % of participants
NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 16 Participants as posted
show 2 more results
7.3% (n=233) vs 4.2% (n=239) Exemestane*
NCT00253422 · Phase 3 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
22.8% (n=206) vs 29.4% (n=187) Capecitabine*
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 47 Participants as posted
Clinical Benefit 24.3% (n=226) vs 23.8% (n=239) Exemestane
event count · % of participants
NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 55 Participants as posted
show 2 more results
28.3% (n=233) vs 23.8% (n=239) Exemestane*
NCT00253422 · Phase 3 · registry result, not featured evidence · combination · converted to % from 66 Participants as posted
76.2% (n=206) vs 82.4% (n=187) Capecitabine*
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 157 Participants as posted
Duration of Clinical Benefit 11.2 vs 12.2 Exemestane months
time to event · months
NCT00253422 · Phase 3 · registry result, not featured evidence
show 2 more results
11.5 vs 12.2 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
18.5 vs 18.1 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
Time to Treatment Failure 3.8 vs 3.4 Exemestane months
time to event · months
NCT00253422 · Phase 3 · registry result, not featured evidence
show 2 more results
3.9 vs 3.4 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
12.4 vs 11.4 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 20.1 vs 22.5 Exemestane months
time to event · months
NCT00253422 · Phase 3 · registry result, not featured evidence
show 4 more results
20.2 vs 22.5 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
33.7 vs 32 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
29.9 vs 26.4 placebo months
NCT00390455 · Phase 3 · registry result, not featured evidence
37.8 vs 38.2 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Global Health Status 3.28 vs 1.97 Capecitabine score
absolute change · score
Global health status / QoL
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Physical Functioning -1.73 vs -2.94 Capecitabine score
absolute change · score
Physical functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination

+ 69 further endpoints in the CSV export.

Breast Cancer

Shared mechanism: Estrogen receptor · full Breast Cancer pipeline

Camizestrant · Etcamah

Marketed by AstraZeneca

Approved in Breast Cancersmall molecule
Reliable signal

NCT04964934 · Phase 3 · active, not recruiting

This was a randomized, triple-blinded, placebo-controlled Phase III trial with an active comparator (continued aromatase inhibitor) in 315 patients, using progression-free survival (a hard clinical endpoint) as the primary measure. The result, reported via an external source since CT.gov has not yet posted results, showed a clear and highly statistically significant benefit for camizestrant (median PFS 16.0 vs 9.2 months, HR 0.44, p<0.00001), meeting the primary endpoint in the favorable direction.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: April 2027 · NCT05774951 (registry estimate)

Reported efficacy

Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) (From randomization until the earlier of the progression event or death (approximately 2 years)): SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 (met)

Result source: NCT04964934

Fulvestrant · Faslodex

Marketed by AstraZeneca

Approved in Breast Cancersmall molecule
Partial signal

NCT00635713 · Phase 3 · completed

The trial randomized an estimated 588 participants and used double blinding to compare two active treatment groups: fulvestrant 125 mg plus anastrozole versus fulvestrant 250 mg plus anastrozole. Its primary endpoint was time to tumor progression, a clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

ClinicalTrials.gov records both arms as fulvestrant plus anastrozole. The published North American Trial 0021 (Osborne 2002) randomized fulvestrant 250 mg monthly against anastrozole 1 mg daily, double-blind and double-dummy.

Next expected readout: December 2026 · NCT07163481 (registry estimate)

Reported efficacy

Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59) (met)

Result source: NCT01602380

Results for Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Camizestrant
SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 NCT04964934 · Phase 3 · design grade: strong · publication or press release
Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81) NCT04588298 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. Camizestrant: 4 of 4 rows · Fulvestrant: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCamizestrantFulvestrant
Dropout rate
3.3%75 mga
NCT04588298 · Phase 2
show 4 more results
3.3%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
89.1%500 mga
NCT01602380 · Phase 3 · combination
show 39 more results
47.5%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
31.7%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
21.2%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
1.2%
NCT02447328 · Phase 4 · registry result, not featured evidence
0%Faslodex + Arimidex
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
0%Faslodex + Placebo
NCT00253422 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
—Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
—Anastrozole & Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneArm I Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
n/a: no completion milestoneArm II Anastrozole and Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
21.6%
NCT00390455 · Phase 3 · registry result, not featured evidence
32.4%500 mg
NCT01300351 · Phase 3 · registry result, not featured evidence
64.7%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
1.1%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
87.5%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
8.2%
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
99.2%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
100%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
92.1%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
0%Crizotinib Oral Capsule [Xalkori]
NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy
0%Crizotinib Oral Capsule [Xalkori]
NCT03620643 · Phase 2 · registry result, not featured evidence · combination
10.1%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
6.3%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
1.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
1.6%
NCT02536742 · Phase 2 · registry result, not featured evidence
—Crossover: Neratinib + Fulvestrant
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
9.1%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
12.5%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
3.4%Arm B: Fulvestrant + Bortezomib
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
—Arm C: Crossover From Arm A at Pro
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
0%
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
—500 mga
NCT01602380 · Phase 3 · combination
show 39 more results
10%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
3.2%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
1.5%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
—
NCT02447328 · Phase 4 · registry result, not featured evidence
—Faslodex + Arimidex
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
—Faslodex + Placebo
NCT00253422 · Phase 3 · registry result, not featured evidence
2%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
—Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
—Anastrozole & Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
1.4%Arm I Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
3.4%Arm II Anastrozole and Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
11.5%
NCT00390455 · Phase 3 · registry result, not featured evidence
0%500 mg
NCT01300351 · Phase 3 · registry result, not featured evidence
5%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
—
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
—
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
—
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
15.7%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
11.1%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
10.3%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Crizotinib Oral Capsule [Xalkori]
NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy
—Crizotinib Oral Capsule [Xalkori]
NCT03620643 · Phase 2 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
—
NCT02536742 · Phase 2 · registry result, not featured evidence
—Crossover: Neratinib + Fulvestrant
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
—Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
—Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
—Arm B: Fulvestrant + Bortezomib
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
—Arm C: Crossover From Arm A at Pro
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
—
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
—
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
0%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
17.1%500 mga
NCT01602380 · Phase 3 · combination
show 39 more results
25%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
7.9%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
6.6%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
11.1%
NCT02447328 · Phase 4 · registry result, not featured evidence
16.9%Faslodex + Arimidex
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
13.8%Faslodex + Placebo
NCT00253422 · Phase 3 · registry result, not featured evidence
14.1%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
6.2%Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
13.8%Anastrozole & Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
—Arm I Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
—Arm II Anastrozole and Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
8.5%
NCT00390455 · Phase 3 · registry result, not featured evidence
3.7%500 mg
NCT01300351 · Phase 3 · registry result, not featured evidence
15.6%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
38%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
15.7%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
25%
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
29.1%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
0%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
38.1%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30.2%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
66.7%Crizotinib Oral Capsule [Xalkori]
NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy
18.5%Crizotinib Oral Capsule [Xalkori]
NCT03620643 · Phase 2 · registry result, not featured evidence · combination
19.5%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
30.8%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
27.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
73%
NCT02536742 · Phase 2 · registry result, not featured evidence
0%Crossover: Neratinib + Fulvestrant
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
18.2%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
37.5%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
10.5%Arm B: Fulvestrant + Bortezomib
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
18.5%Arm C: Crossover From Arm A at Pro
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
6.3%
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
23.1%
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
75 mga
nausea 13.3%
fatigue 6.7%
headache 6.7%
NCT04588298 · Phase 2
show 4 more results
75 mg
visual impairment 20%
headache 10%
photopsia 10%
NCT04588298 · Phase 2
300 mg
hypertension 23.1%
visual impairment 23.1%
photopsia 15.4%
NCT04588298 · Phase 2
150 mg
visual impairment 15.2%
diplopia 12.1%
photopsia 12.1%
NCT04588298 · Phase 2
150 mg
visual impairment 24.1%
diplopia 17.2%
hypertension 13.8%
NCT04588298 · Phase 2
500 mga
arthralgia 18.4%
fatigue 12.7%
hot flush 11.4%
NCT01602380 · Phase 3 · combination
show 32 more results
hyperglycaemia 90%
stomatitis 37.5%
diarrhoea 35%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 28.6%
anaemia 22.2%
fatigue 20.6%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 29.9%
neutropenia 24.8%
anaemia 23.4%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
myalgia 12.3%
nausea 12.3%
back pain 11.1%
NCT02447328 · Phase 4 · registry result, not featured evidence
lethargy 64.5%
arthralgia 42%
hot flush 37.2%
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
lethargy 64.4%
vomiting 44.9%
arthralgia 43.6%
NCT00253422 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 63.1%
fatigue 51%
hypertension 36.9%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
fatigue (asthenia, lethargy, malaise) 60.2%
hot flashes/flushes 45.7%
pain - joint 45.1%
NCT00075764 · Phase 3 · registry result, not featured evidence
fatigue (asthenia, lethargy, malaise) 63.2%
hot flashes/flushes 54.3%
pain - joint 44%
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
diarrhea 62.4% (placebo 21.9%)
fatigue 55.3% (placebo 53.3%)
rash acneiform 41.1% (placebo 4.4%)
NCT00390455 · Phase 3 · registry result, not featured evidence
500 mg
injection site reaction 11%
pyrexia 10.1%
fatigue 8.3%
NCT01300351 · Phase 3 · registry result, not featured evidence
arthralgia 11.7%
fatigue 10.5%
nausea 9%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 92.4%
white blood cell decreased 87%
fatigue 84.8%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 92.2%
nausea 52.9%
stomatitis 41.2%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
fatigue 83.3%
anemia 62.5%
neutrophil count decreased 60.4%
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 64.6%
hyperglycaemia 59.8%
nausea 46.5%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
asthenia 100%
blood creatinine increased 100%
diarrhoea 100%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 68.3%
hyperglycaemia 64.3%
nausea 54%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
hyperglycaemia 67.5%
diarrhoea 54%
nausea 40.5%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 70%
hyperglycaemia 60%
fatigue 50%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
alanine aminotransferase increased 66.7%
aspartate aminotransferase increased 66.7%
dyspnea 50%
NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy
aspartate aminotransferase increased 74.1%
nausea 74.1%
alanine aminotransferase increased 63%
NCT03620643 · Phase 2 · registry result, not featured evidence · combination
150 mg + 8 mg/kg
diarrhoea 77.9%
fatigue 53.2%
nausea 41.6%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
150 mg + 8 mg/kg + 500 mg
diarrhoea 79.5%
fatigue 57.7%
nausea 48.7%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
white blood cell count decreased 96.3%
neutrophil count decreased 87%
anemia 79.6%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
vomiting 60%
anorexia 40%
constipation 40%
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
diarrhea 81.8%
anorexia 63.6%
aspartate aminotransferase increased 45.5%
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
diarrhea 91.7%
fatigue 50%
nausea 50%
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
hemoglobin - low 61.4%
thrombocytopenia 61.4%
nausea 59.6%
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
hemoglobin - low 55.6%
thrombocytopenia 55.6%
diarrhea 51.9%
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
fatigue 53.1%
nausea 50%
achiness 43.8%
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
fatigue 76.9%
anorexia 61.5%
pain 53.8%
NCT01441947 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Fulvestrant

PFS 16.6 vs 13.8 Anastrozole months500 mg
time to event · months
NCT01602380 · Phase 3 · combination
show 9 more results
8.3 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
5.7 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
4.8 vs 3.5 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence
4.1 vs 3.5 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
7.5 vs 9.4 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
8 vs 10.6 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
4.7 vs 3.8 placebo months
NCT00390455 · Phase 3 · registry result, not featured evidence
4.1 vs 3.8 placebo months
NCT00390455 · Phase 3 · registry result, not featured evidence
5.9 vs 3.3 placebo months
NCT00390455 · Phase 3 · registry result, not featured evidence
All-cause Mortality 68.3% (n=230) vs 67.7% (n=232) Anastrozole500 mg
absolute value · percentage points
NCT01602380 · Phase 3 · combination
ORR 46.1% (n=193) vs 44.9% (n=196) Anastrozole500 mg
responder rate · % of participants
NCT01602380 · Phase 3 · combination
show 5 more results
32.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
13.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
20% (n=101) vs 9% (n=103) placebo
NCT00390455 · Phase 3 · registry result, not featured evidence
13% (n=32) vs 23% (n=32) placebo
NCT00390455 · Phase 3 · registry result, not featured evidence
38% (n=8) vs 17% (n=13) placebo
NCT00390455 · Phase 3 · registry result, not featured evidence
Duration of Response 20 vs 13.2 Anastrozole months500 mg
time to event · months
NCT01602380 · Phase 3 · combination
show 6 more results
12.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
9.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
10.2 vs 12.8 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence
8.7 vs 12.8 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
9.7 vs 11.2 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
22.3 vs 18.2 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
Clinical Benefit 78.3% (n=230) vs 74.1% (n=232) Anastrozole500 mg
responder rate · % of participants
NCT01602380 · Phase 3 · combination
show 3 more results
58.2% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
45.6% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
55% (n=258) vs 55.1% (n=256) Anastrozole
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
ORR 7.1% (n=226) vs 4.2% (n=239) Exemestane
event count · % of participants
NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 16 Participants as posted
show 2 more results
7.3% (n=233) vs 4.2% (n=239) Exemestane*
NCT00253422 · Phase 3 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
22.8% (n=206) vs 29.4% (n=187) Capecitabine*
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 47 Participants as posted
Clinical Benefit 24.3% (n=226) vs 23.8% (n=239) Exemestane
event count · % of participants
NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 55 Participants as posted
show 2 more results
28.3% (n=233) vs 23.8% (n=239) Exemestane*
NCT00253422 · Phase 3 · registry result, not featured evidence · combination · converted to % from 66 Participants as posted
76.2% (n=206) vs 82.4% (n=187) Capecitabine*
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 157 Participants as posted
Duration of Clinical Benefit 11.2 vs 12.2 Exemestane months
time to event · months
NCT00253422 · Phase 3 · registry result, not featured evidence
show 2 more results
11.5 vs 12.2 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
18.5 vs 18.1 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
Time to Treatment Failure 3.8 vs 3.4 Exemestane months
time to event · months
NCT00253422 · Phase 3 · registry result, not featured evidence
show 2 more results
3.9 vs 3.4 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
12.4 vs 11.4 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 20.1 vs 22.5 Exemestane months
time to event · months
NCT00253422 · Phase 3 · registry result, not featured evidence
show 4 more results
20.2 vs 22.5 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
33.7 vs 32 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
29.9 vs 26.4 placebo months
NCT00390455 · Phase 3 · registry result, not featured evidence
37.8 vs 38.2 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Global Health Status 3.28 vs 1.97 Capecitabine score
absolute change · score
Global health status / QoL
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Physical Functioning -1.73 vs -2.94 Capecitabine score
absolute change · score
Physical functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination

+ 68 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camizestrant's landscape · Fulvestrant's landscape